Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFPT1 | Q06210 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | CASR | P41180 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20178594 | 0.90 | GFPT1 (0.34) | GFPT1 | |
| SCHEMBL16447372 | 0.90 | GFPT1 (0.34) | GFPT1 | |
| SCHEMBL20178606 | 0.83 | OTC (0.46) | NOS3NOS1NOS2SLC1A3SLC1A1 | |
| SCHEMBL16446997 | 0.83 | OTC (0.46) | NOS3NOS1NOS2SLC1A3SLC1A1 | |
| SCHEMBL23579337 | 0.82 | DDAH1 (0.43) | NOS3NOS1NOS2 | |
| SCHEMBL16446929 | 0.82 | NOS3 (0.43) | NOS3NOS1NOS2SLC1A3SLC1A1 | |
| SCHEMBL15546760 | 0.82 | DDAH1 (0.43) | NOS3NOS1NOS2 | |
| SCHEMBL15618248 | 0.82 | DDAH1 (0.43) | NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL23629020 | 0.81 | DDAH1 (0.42) | NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL23629018 | 0.81 | DDAH1 (0.42) | NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026008-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240026008-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | SUTRO BIOPHARMA, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | SUTRO BIOPHARMA, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11708413-B2 | Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates | SUTRO BIOPHARMA, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708413-B2 | Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates | SUTRO BIOPHARMA, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230139442-A1 | MODIFIED AMINO ACIDS | SUTRO BIOPHARMA, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230139442-A1 | MODIFIED AMINO ACIDS | SUTRO BIOPHARMA, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11548852-B2 | Modified amino acids | SUTRO BIOPHARMA, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4074728-A1 | MODIFIED PEPTIDES COMPRISING AN AZIDO GROUP | Sutro Biopharma, Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20160251336-A1 | MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| WO-2015054658-A1 | MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015006555-A2 | ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20140066598-A1 | Modified Amino Acids | SUTRO BIOPHARMA, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066598-A1 | Modified Amino Acids | SUTRO BIOPHARMA, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2014036492-A1 | MODIFIED AMINO ACIDS COMPRISING AN AZIDO GROUP | SUTRO BIOPHARMA, INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| US-20140051836-A1 | Modified Fc Proteins Comprising Site-Specific Non-Natural Amino Acid Residues, Conjugates of the Same, Methods of Their Preparation and Methods of Their Use | SUTRO BIOPHARMA, INC. | 2014-02-20 | — | — | US | disclosed |
| US-20140051836-A1 | Modified Fc Proteins Comprising Site-Specific Non-Natural Amino Acid Residues, Conjugates of the Same, Methods of Their Preparation and Methods of Their Use | SUTRO BIOPHARMA, INC. | 2014-02-20 | — | — | US | disclosed |
| US-20140046030-A1 | ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140046030-A1 | ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051836-A1 | Modified Fc Proteins Comprising Site-Specific Non-Natural Amino Acid Residues, Conjugates of the Same, Methods of Their Preparation and Methods of Their Use | FCGR2A, FCGR3B, FCGR1A | GFPT1 373/4885NOS3 2243/4885NOS1 2820/4885 |
| US-11548852-B2 | Modified amino acids | PTMS, DNPEP, ANPEP | GFPT1 401/4885NOS3 1710/4885NOS1 2223/4885 |
| US-20240026008-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | CD74, CD63, CD99 | GFPT1 4316/4885NOS3 4646/4885NOS1 4435/4885 |
| US-11708413-B2 | Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates | CD74, CD63, CD99 | GFPT1 4241/4885NOS3 4575/4885NOS1 4367/4885 |
| US-20140066598-A1 | Modified Amino Acids | PTMS, DNPEP, ANPEP | GFPT1 401/4885NOS3 1710/4885NOS1 2223/4885 |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | FCGR1A, FCGR2A, FCGRT | GFPT1 3002/4885NOS3 2910/4885NOS1 3676/4885 |
| US-20230139442-A1 | MODIFIED AMINO ACIDS | PTMS, DNPEP, ANPEP | GFPT1 401/4885NOS3 1710/4885NOS1 2223/4885 |
| US-20160251336-A1 | MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE | DNPEP, SLC1A5, AADAT | GFPT1 359/4885NOS3 3852/4885NOS1 3608/4885 |
| US-20140046030-A1 | ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | DNPEP, LNPEP, ANPEP | GFPT1 559/4885NOS3 2411/4885NOS1 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.